Factors predicting residual β-cell function in the first year after diagnosis of childhood type 1 diabetes☆
References (32)
- et al.
Cyclo-soprin increases the rate and length of remission in insulin-dependent diabetes of recent onset
Lancet
(1986) - et al.
Conference: Immunosuppression in the treatment of insulin-dependent (type 1) diabetes
- et al.
Separation of free and antibody-bound insulin in plasma using a bench ultracentrifuge (Beckman ‘Air fuge’)
Clin. Chim. Acta
(1984) - et al.
Value of insulin autoantibodies as serum markers for insulin-dependent diabetes mellitus
Lancet
(1985) - et al.
Post-initial remission in diabetic children — an analysis of 178 cases
Acta Paed. Scand.
(1982) - et al.
C-peptide in juvenile diabetics beyond the post-initial remission period
Acta Paed. Scand.
(1977) - et al.
Prevalence of residual beta cell function in insulin dependent diabetics in relation to age at onset and duration of diabetes
Diabetes
(1978) - et al.
Prevalence of residual β-cell function in insulintreated diabetics evaluated by plasma C-peptide response to intravenous glucagon
Diabetologia
(1977) - et al.
Factors affecting and patterns of residual insulin secretion during the first year of type 1 (insulin-dependent) diabetes mellitus in children
Diabetologia
(1987) Residual insulin secretion in IDDM
Arch. Dis. Child.
(1986)
Factors influencing the magnitude, duration and rate of fall of β-cell function in type 1 (insulin-dependent) diabetic children followed for 2 years from their clinical diagnosis
Diabetologia
Correlation between residual β-cell function and islet cell antibodies in newly diagnosed type 1 diabetes
Diabetes
Increased reduction in fasting C-peptide is associated with islet cell antibodies in type 1 (insulin-dependent) diabetic patients
Diabetologia
Prospective study of predictors of β-cell survival in type 1 diabetes
Diabetes
Evidence of delayed β-cell destruction in type 1 (insulin-dependent) diabetic patients with persisting complement-fixing cytoplasmic islet cell antibodies
Diabetologia
Insulin secretory reserve in insulin-dependent patients at the time of diagnosis and the first 180 days of insulin treatment
Acta Endocrinol.
Cited by (39)
Influence of remission and its duration on development of early microvascular complications in young adults with type 1 diabetes
2015, Journal of Diabetes and its ComplicationsCitation Excerpt :However, complete cessation of insulin therapy usually leads to rapid depletion of beta cell insulin-producing ability, and it is not the recommended therapeutic option (DCCT, 1998; Scholin, Berne, Schvarcz, Karlsson, & Bjork, 1999). Most criteria for remission take into consideration the following parameters: glycated hemoglobin level (HbA1c), demand for exogenous insulin (number of units/kg body weight/day), and serum C-peptide concentration (Abdul-Rasoul et al., 2006; Bonfati et al., 1998; Chase, MacKenzie, Burdick, Fiallo-Scharer, & Walravens, 2004; Chloot et al., 2007; Couper, Hudson, Werther, Warne, & Court, 1991; Scholin et al., 1999, 2004). It is known that maintaining residual insulin secretion facilitates good metabolic control of diabetes and decreases the risk of hypoglycemia (Ali & Dayan, 2009; Fukuda et al., 1988).
Immunopathology of Type 1 Diabetes and Immunomodulatory Effects of Stem Cells: A Narrative Review of the Literature
2022, Endocrine, Metabolic and Immune Disorders - Drug TargetsGlucagon stimulation test as a possible predictor of residual β-cell function
2021, Pediatrics InternationalClinical remission of type 1 diabetes predicts higher insulin sensitivity at 7 years from diagnosis of the disease
2020, Diabetes Technology and Therapeutics
- ☆
Presented in part at the IXth International Workshop on the Immunology of Diabetes, Melbourne, Australia, 27–29 November, 1988.